OmniAb, Inc. (OABIW) stock
OABIWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as OABI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 10/309% above fair value
$0.41−0.01 (-2.38%)
Close on Oct 30, 2026Market cap $742.95MP/E –Yield –
OmniAb r&d expenses
Research and development expenses are spending on new products and technology.
OmniAb's R&D Expenses for the twelve months ending Sep 30, 2026 was $42.69M, down 9.5% year over year. For fiscal 2025 it was $47.75M, down 13.3% from the year before. The highest annual figure on record is $56.53M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.75M | -13.3% |
| FY2024 | Dec 31, 2024 | $55.11M | -2.5% |
| FY2023 | Dec 31, 2023 | $56.53M | +16.9% |
| FY2022 | Dec 31, 2022 | $48.36M | +23.3% |
| FY2021 | Dec 31, 2021 | $39.23M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.55M | -8.0% |
| Q2 FY2026 | Jun 30, 2026 | $9.59M | -11.8% |
| Q1 FY2026 | Mar 31, 2026 | $9.64M | -23.5% |
| Q4 FY2025 | Dec 31, 2025 | $13.91M | +4.5% |
| Q3 FY2025 | Sep 30, 2025 | $10.38M | -22.1% |
| Q2 FY2025 | Jun 30, 2025 | $10.86M | -22.0% |
| Q1 FY2025 | Mar 31, 2025 | $12.60M | -13.4% |
| Q4 FY2024 | Dec 31, 2024 | $13.31M | -9.9% |
| Q3 FY2024 | Sep 30, 2024 | $13.32M | -4.0% |
| Q2 FY2024 | Jun 30, 2024 | $13.94M | -1.4% |
| Q1 FY2024 | Mar 31, 2024 | $14.55M | +5.8% |
| Q4 FY2023 | Dec 31, 2023 | $14.77M | +14.3% |
| Q3 FY2023 | Sep 30, 2023 | $13.87M | +5.1% |
| Q2 FY2023 | Jun 30, 2023 | $14.13M | +23.1% |
| Q1 FY2023 | Mar 31, 2023 | $13.76M | +27.7% |
| Q4 FY2022 | Dec 31, 2022 | $12.92M | – |
| Q3 FY2022 | Sep 30, 2022 | $13.19M | – |
| Q2 FY2022 | Jun 30, 2022 | $11.48M | – |
| Q1 FY2022 | Mar 31, 2022 | $10.77M | – |